The drug candidate PST-674 - a proprietary inhibitor of DYRK1A.

Pharmasum Therapeutics has developed the DYRK1A kinase inhibitor PST-674 by using advanced drug design technologies. In collaboration with The Arctic University in Tromsø (UiT) extensive X-ray crystallographic studies established the Structure-Activity Relationships (SAR), and subsequent Lead Optimization chemistry led to the development of the optimized small-molecule PST-674.